GYRE THERAPEUTICS INC (GYRE)

Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update...

Gyre Therapeutics Breaks Above 200-Day Moving Average - Bullish for GYRE

Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis

Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis

Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis...

Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference

Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference

Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference...

Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

GYRE Stock Earnings: Gyre Therapeutics Reported Results for Q2 2024

Gyre Therapeutics just reported results for the second quarter of 2024.

GYRE Stock Earnings: Gyre Therapeutics Reported Results for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gyre Therapeutics (NASDAQ:GYRE) just reported results for the second quarter of...

Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update...

Gyre Therapeutics to Present at Sidoti Virtual Investor Conference

Gyre Therapeutics to Present at Sidoti Virtual Investor Conference

Gyre Therapeutics to Present at Sidoti Virtual Investor Conference...

Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors

Relative Strength Alert For Gyre Therapeutics

GYRE Makes Bullish Cross Above Critical Moving Average

Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia

Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia

Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia...

Oversold Conditions For Gyre Therapeutics

Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology

Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology

Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology ...

Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension

Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension

Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension...

Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes

Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes

Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes...

Gyre Therapeutics is Now Oversold (GYRE)

GYRE Stock Earnings: Gyre Therapeutics Reported Results for Q1 2024

Gyre Therapeutics just reported results for the first quarter of 2024.

GYRE Stock Earnings: Gyre Therapeutics Reported Results for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gyre Therapeutics (NASDAQ:GYRE) just reported results for the first quarter of ...

Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update...

7 A-Rated Aggressive Biotech Stocks to Bet On in 2024

We’re using the Portfolio Grader to find the best biotech stocks to buy in today’s market. Each of these stocks get top grades.